rawfin.tv
Trump Administration Finalizes Initial Drug Pricing Deals, Targets Further Reductions
RegulationstocksAI Generated

Trump Administration Finalizes Initial Drug Pricing Deals, Targets Further Reductions

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

The Trump administration has concluded its first round of drug pricing negotiations, including a deal with Regeneron, as part of a broader initiative to lower pharmaceutical costs. The White House indicated plans to pursue additional agreements, signaling continued pressure on drug manufacturers.

Drug PricingPharmaceuticalsHealthcare PolicyUS RegulationRegeneron

Related Articles

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

stocks
Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

stocks
Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

stocks
Barclays Workforce Trimmed 5% as Bank Increases Focus on AI

Barclays Workforce Trimmed 5% as Bank Increases Focus on AI

stocks